Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

PDE5 Inhibitor Pivotal Evidence

Cochrane Reviews and Pivotal RCTs of Sildenafil, Tadalafil, Vardenafil, Avanafil for ED

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

118 human trials, Tens of thousands across 100+ RCTs. The written rationale for this grade is still being prepared.

FDA
FDA-approved drug class backed by Cochrane-level evidence

Reference only. Not medical advice.

What can go wrong

Absolute contraindication with nitrates - the combination can cause life-threatening hypotension; caution with alpha-blockers and in unstable cardiovascular disease. Common effects: headache, flushing, dyspepsia, nasal congestion, and (sildenafil/vardenafil) transient blue-tinged vision; rare events include NAION (sudden vision loss) and priapism.

This is something to take to a clinician. The Atlas can tell you what is known about pde5 inhibitor pivotal evidence in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Phosphodiesterase type 5 (PDE5) inhibitors are supported by one of the largest randomized evidence bases in urology: scores of placebo-controlled RCTs and Cochrane systematic reviews consistently show significant improvement in erectile function, successful intercourse, and patient/partner satisfaction across diverse ED etiologies. This dossier treats that body of evidence - the Goldstein 1998 sildenafil registration trial through later Cochrane syntheses - as a single reference object. The class is first-line per the AUA, EAU, and ISSM, and is among the few interventions in this library graded grade 5.

The deepest randomized evidence base in all of men's sexual medicine.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Vasculogenic ED
  • Psychogenic ED (adjunct)
  • Post-prostatectomy ED (lower response)
  • Diabetic ED (lower response)
  • BPH/LUTS (tadalafil)

How it works

PDE5 inhibitors block degradation of cyclic GMP in penile smooth muscle, prolonging nitric-oxide-driven vasodilation so that, in response to sexual stimulation, blood fills the corpora cavernosa and produces a firmer, more sustained erection. They enable, but do not initiate, an erection.

Where the evidence is weaker

PDE5 inhibitors are powerful but not universal. Response rates fall in diabetic ED, after radical prostatectomy with nerve damage, and in severe vasculogenic disease. They do nothing without sexual stimulation, do not cure underlying vascular disease, and roughly 30% of men either do not respond or cannot tolerate them. The evidence base is strongest for efficacy and short-term safety; very-long-term and rare-harm questions (e.g., debated melanoma/vision associations) are less settled.

What people get wrong

  • Often saidA PDE5 inhibitor will give any man an instant erection

    ActuallyThey require sexual stimulation to work, fail or are poorly tolerated in roughly a third of men, and respond less well in diabetic and post-prostatectomy ED.

  • Often saidBigger doses give bigger erections

    ActuallyBeyond the effective dose there is no added efficacy, only more side effects.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

Sildenafil emerged serendipitously from a Pfizer angina program when trial participants reported erections. Goldstein's 1998 NEJM trial and parallel registration studies led to FDA approval that year, transforming ED from a stigmatized, surgery/injection-managed condition into a treatable, oral, mainstream one. Tadalafil and vardenafil followed in 2003, avanafil in 2012, and generics from 2017-2018.

  1. 1998Goldstein NEJM sildenafil trial; Viagra approved
  2. 2002Cochrane review confirms class efficacy; tadalafil/vardenafil trials
  3. 2003Cialis and Levitra approved
  4. 2012Avanafil (Stendra) approved
  5. 2017-2018Generic sildenafil and tadalafil arrive, collapsing prices

What the trials could not show

Limits of the studies themselves, as distinct from limits of the treatment.

  • Most pivotal trials were industry-sponsored; many used surrogate questionnaire endpoints (IIEF, SEP) rather than long-term outcomes; trial populations often excluded severe comorbidity; reduced efficacy in diabetic and post-surgical ED; long-term and rare-harm signals less rigorously characterized than efficacy.

What we do not know

  • What are the true very-long-term safety outcomes?
  • Are the debated melanoma/vision associations causal?
  • How best to manage the ~30% of non-responders?

At a glance

Evidence base
100+ placebo-controlled RCTs; multiple Cochrane reviews
Class
Oral PDE5 inhibitors
First approval
Sildenafil (Viagra), 1998
Primary endpoints
IIEF erectile-function domain; SEP2/SEP3 (penetration/maintenance) success rates
Guideline status
First-line (AUA, EAU, ISSM)
Typical efficacy
~60-80% of men report improved erections vs ~20-30% placebo, etiology-dependent

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about PDE5 Inhibitor Pivotal Evidence. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Goldstein et al., sildenafil pivotal trial (NEJM)1998

    Dose-response and flexible-dose RCTs: ~69-74% of attempts ended in successful intercourse on sildenafil vs ~22% placebo; established Viagra as the first effective oral ED drug

  • Cochrane review of sildenafil for ED2002

    Confirmed consistent, significant benefit across dozens of RCTs for varied ED causes

  • Tadalafil registration trials (Brock et al.)2002

    Up to 36-hour window of efficacy; established the 'weekend pill' and later daily low-dose option

  • Avanafil pivotal trials (REVIVE/REVIVE-Diabetes)2012

    Fast onset (as little as 15 min) with efficacy in general and diabetic ED populations

  • Network meta-analyses of PDE5 inhibitors2010s-2020s

    All four agents efficacious; differences are mainly onset, duration, and side-effect profile rather than peak efficacy